Furthermore, ADD3 has already been implicated in GBM progression, therapeutic resistance, and cell motility (Kiang et al, 2020; Mariani et al, 2001; Poon et al, 2015; Rani et al, 2013; van den Boom et al, 2003). The gene discussed is ADD3; the disease is glioblastoma.